^
Association details:
| Biomarker: | EGFR T790M + EGFR L792F |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Blockade of STAT3/IL-4 overcomes EGFR T790M-cis-L792F-induced resistance to osimertinib via promoting M2 macrophages polarization.
Published date:
05/26/2022
Excerpt:
Circulating tumor DNA-based sequencing data of 1382 patients with osimertinib resistance were collected to illustrate the prevalence of L792F mutation....The concomitant EGFR L792 was identified as an independent mutation following the acquisition of T790M after osimertinib resistance, in that 5 of the 946 patients with osimertinib resistance harbored EGFR L792F-cis mutation….Our results provided solid evidence of EGFR T790M-cis-L792F mutation as a factor inducing osimertinib resistance.
DOI:
10.1200/JCO.2022.40.16_suppl.e20552
